Intravenous oxytocin regimens in patients undergoing cesarean delivery: a systematic review and network meta-analysis of cluster-based groups.
Thrivikrama Padur TantryHarish KaranthSaravana AnniyappaPramal K ShettyMadhusudan UpadyaSunil P ShenoyDinesh KadamPublished in: Journal of anesthesia (2022)
Information on evaluations of different oxytocin regimens used to prevent post-partum hemorrhage during cesarean delivery is scarce, and there is a lack of statistically pooled results for comparative doses. In this review, we aimed to analyze the effectiveness of different oxytocin regimens used and rank them accordingly. We performed a meta-analysis of randomized controlled trials (RCTs) reporting the incidence of additional uterotonic (AUT) use or amount of blood loss during cesarean delivery, where different oxytocin regimens were compared. Cluster analysis was used to define different clusters of oxytocin therapy based on the identified variable regimens. During the frequentist network meta-analysis, all clusters were compared to bolus clusters of dose range 3-5 IU. Data from 33 RCTs (6741 patients) to 26 RCTs (5422 patients) were assessed for AUT use and blood loss, respectively. Pairwise meta-analysis revealed a significant reduction in the use of AUTs or blood loss was recorded for bolus-infusion combination regimens. The network meta-analysis found that combined bolus-infusion regimens of (i) 3-5 IU and 0.25-1 IU/min or (ii) 3-5 IU and < 0.25 IU/min had statistically significant results for lowest consumption of AUTs (Ranks 1 and 2, respectively); whereas with the latter's use, the lowest blood loss (Rank 2) was observed. In contrast, the dose range, > 5 IU regimen was associated with higher side effects (lowest rank). During cesarean delivery, a significant reduction in the use of AUTs or blood loss (Rank 2) was recorded for bolus-infusion combination regimens. High doses did not have enough evidence to draw meaningful conclusions.
Keyphrases
- systematic review
- end stage renal disease
- chronic kidney disease
- patients undergoing
- newly diagnosed
- ejection fraction
- meta analyses
- low dose
- randomized controlled trial
- prognostic factors
- peritoneal dialysis
- magnetic resonance
- magnetic resonance imaging
- stem cells
- healthcare
- emergency department
- single cell
- computed tomography
- case control
- mesenchymal stem cells
- bone marrow
- clinical trial
- contrast enhanced
- patient reported
- social media